Johnson & Johnson Innovation invests $8.4M in Mauna Kea Technologies

Johnson & Johnson Innovation invested about $8.4 million in medical device company Mauna Kea Technologies, acquiring 5.3 million shares.

Advertisement

J&JI is Johnson & Johnson’s venture capital arm. J&J will receive no board representation as a result of its investment. The companies are currently working to develop tools to diagnose and treat lung cancer. Mauna Kea developed the Cellvizio platform, which can be used to treat an array of conditions, including Barrett’s esophagus. The companies are working to use the Cellvizio platform and the AQ-Flex-19 Confocal Miniprobe to treat lung cancer.

More articles on gastroenterology:
Arkansas health system acquires surgical practice
Work progressing on Quincy Medical Group’s surgery center — 3 insights
UM Shore Regional Health purchases 9+ acres for campus with surgery center — 4 insights

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.